Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Obesity drug makers jockey for position as analysts praise Vivus
Marketwatch
Thursday, October 3, 2013 - 5:29pm
tags:
obesity, Vivus, Belviq, Arena Pharmaceuticals, Contrave, Orexigen, Qsymia
Pfizer, Ligand Win U.S. Approval for Hot Flash Therapy
Bloomberg
Thursday, October 3, 2013 - 5:25pm
tags:
Pfizer, Ligand, hot flashes, menopause, osteoporosis, FDA, Duavee
Things Just Got A Little Brighter For Vivus
Seeking Alpha
Thursday, October 3, 2013 - 11:58am
tags:
Vivus, Qsymia
Top Biotechs Set to Win in the War on Cancer
Yahoo/Wall St 24-7
Thursday, October 3, 2013 - 11:57am
tags:
biotech, Biomarin, Immunogen, Ariad Pharmaceuticals, Amgen, Celgene, Gilead Sciences
New Type of Drug to Lower LDL Looks Promising
Med Page Today
Thursday, October 3, 2013 - 11:33am
tags:
LDL cholesterol, Alnylam, PCSK9 inhibitors
PhRMA Sues The Feds Over 340B Discounts On Orphan Drugs
Pharmalot
Thursday, October 3, 2013 - 11:25am
tags:
PhRMA, drug discounts, orphan drugs
Amarin informed by FDA that Oct. 16 advisory committee meeting will take place
Yahoo/Fly on the Wall
Thursday, October 3, 2013 - 11:22am
tags:
Amarin, FDA, advisory panels, Vascepa
Top 15 Drug Launch Superstars
Fierce Pharma
Thursday, October 3, 2013 - 10:35am
tags:
drug launches, Eylea, Regeneron, Bayer, Tecfidera, Biogen Idec, Kalydeco, Vertex Pharmaceuticals, Kadcyla, Roche, Genentech, Victoza, Novo Nordisk, Gilenya, Novartis, Zytiga, JNJ, Yervoy, Bristol-Myers Squibb, Stribild, Gilead Sciences Xtandi, Medivation, Astellas, Afinitor, Amgen, Prolia, Stelara, Kyprolis, Xarelto, ONYX Pharmaceuticals
The Numbers Behind The Job Cuts -- 5 Reasons Why Merck & Co. Was Forced To Wield The Axe
Forbes
Thursday, October 3, 2013 - 10:29am
tags:
Merck, layoffs, Pfizer, Januvia, R&D
Novartis sees limited impact from Japan Diovan scandal
Reuters
Thursday, October 3, 2013 - 9:11am
tags:
Novartis, Japan, Diovan
Dendreon: Time To Prove Itself Or Perish
Seeking Alpha
Thursday, October 3, 2013 - 9:11am
tags:
Dendreon, prostate cancer, JNJ, Provenge, Medivation
Eli Lilly's ramucirumab for gastric cancer shows positive Phase III results
Yahoo/Fly on the Wall
Thursday, October 3, 2013 - 9:09am
tags:
Eli Lilli, ramucirumab, gastric cancer
Lilly Challenged to Hit Sales Goal Announces Buyback
Bloomberg
Thursday, October 3, 2013 - 9:09am
tags:
Eli Lilly
Astex Pharma shareholder opposes $886 mln bid by Otsuka
Yahoo/Reuters
Thursday, October 3, 2013 - 9:08am
tags:
Astex, Otsuka, shareholders, M&A
Judge sweeps aside AstraZeneca shield against Nexium competitor
Fierce Pharma
Wednesday, October 2, 2013 - 2:59pm
tags:
AstraZeneca, Hanmi Pharma, Nexium, Esomezol
With Actavis acquisition complete, Chilcott announces layoffs in N.J.
NJ Biz
Wednesday, October 2, 2013 - 2:58pm
tags:
Actavis, Warner Chilcott, layoffs, M&A
Stryker sues Biomet, sales reps over alleged poaching scheme
Mass Device
Wednesday, October 2, 2013 - 2:54pm
tags:
devices, Biomet, Stryker
Wright Medical Deal Chances Enhanced After Mako: Real M&A
Bloomberg
Wednesday, October 2, 2013 - 2:46pm
tags:
Wright Medical, MAKO, M&A, devices, Stryker
Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude
TheStreet.com
Wednesday, October 2, 2013 - 2:38pm
tags:
Delcath, Zalicus, orphan drugs, Chemosat, liver cancer
Cancer immunotherapies turn a corner in race to megablockbuster market
Fierce Biotech
Wednesday, October 2, 2013 - 10:54am
tags:
cancer immunotherapy, Merck, MK-3475, nivolumab, Bristol-Myers Squibb, Roche, MPDL3280A, PDL-1

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.